Relmada Therapeutics to Present at the Sidoti & Company Fall 2016 Emerging Growth Convention

NEW YORK, Oct. 27, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that it will present at the Sidoti & Company Fall 2016 Emerging Growth Convention to be held Tuesday, November 1, 2016, at the Mariott Marquis in New York City.

The presentation by Dr. Sergio Traversa, Chief Executive Officer of Relmada Therapeutics, is scheduled to begin at 2:25 p.m. Eastern Time on Tuesday, November 1. Individuals interested in attending and scheduling a one-on-one meeting with management should click the link here.

A live webcast of the presentation will be available through the Company's website at www.relmada.com. Please register at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived on the website for 90 days after the conference.

About the Sidoti & Company Emerging Growth Convention

The Sidoti & Company Fall 2016 Emerging Growth Convention will focus on companies with market capitalizations of $600 million and less, connecting their executive management teams with institutional and high-net-worth investors while building interest and visibility into the most overlooked, undervalued segment of the equity market.  Sidoti & Company, founded in 1999, is Wall Street's preeminent provider of equity research generally focused on companies with market capitalizations of under $3 billion.  Sidoti & Company's approach affords institutional investor clients a combination of high-quality research of over 250 companies, a small- and micro-cap company focused nationwide sales effort, broad access to corporate management teams, and extensive trading support. Sidoti & Company serves nearly 500 institutional clients in the U.S., Canada and the U.K., including many leading managers of portfolios with $200 million to $2 billion of assets.  They also hosts a biannual Emerging Growth Convention in New York, and is a provider of company sponsored research.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com. 

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.

Contact

Investor Contact:
Michael Becker, Chief Financial Officer
Relmada Therapeutics Inc.
Tel: 646-677-3857
mbecker@relmada.com

Media Contact:
Lynn Granito
Berry & Company Public Relations
Tel: 212-253-8881
lgranito@berrypr.com

Photo - http://photos.prnewswire.com/prnh/20161026/432806
Logo -  http://photos.prnewswire.com/prnh/20150113/168770LOGO

SOURCE Relmada Therapeutics, Inc.